{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-003465","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.951206+00:00","generated_at":"2026-06-06T20:04:48.486332+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncocyte launches VitaGraft Kidney test for transplant monitoring","bullets":["VitaGraft Kidney, a blood-based dd-cfDNA test for kidney transplant rejection, is now broadly available upon request.","Previously limited to Oncocyte's Early Access Program; official launch announced via LinkedIn on Jan 22, 2024.","Test measures donor-derived cell-free DNA concentrations post-transplantation as indicator for organ damage or rejection."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-003465","json":"https://secwatch.observer/filing/0001493152-24-003465.json","markdown":"https://secwatch.observer/filing/0001493152-24-003465.md","text":"https://secwatch.observer/filing/0001493152-24-003465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224003465/0001493152-24-003465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224003465/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:04:48.486332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}